Dimerix Ltd
DXB
Company Profile
Business description
Dimerix Ltd is a biopharmaceutical company developing new therapies in areas with unmet medical needs. The company is developing four product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for COPD; as well as the proprietary ReceptorHIT assay technology.
Contact
425 Smith Street
FitzroyVIC3065
AUST: +61 1300813321
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
9
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,571.40 | 40.30 | -0.47% |
| CAC 40 | 7,814.39 | 96.10 | -1.21% |
| DAX 40 | 23,889.52 | 232.88 | -0.97% |
| Dow JONES (US) | 41,802.92 | 57.52 | -0.14% |
| FTSE 100 | 8,697.01 | 89.45 | -1.02% |
| HKSE | 23,544.31 | 283.47 | -1.19% |
| NASDAQ | 18,899.09 | 26.45 | 0.14% |
| Nikkei 225 | 36,985.87 | 313.11 | -0.84% |
| NZX 50 Index | 12,662.25 | 40.85 | -0.32% |
| S&P 500 | 5,836.51 | 8.10 | -0.14% |
| S&P/ASX 200 | 8,348.70 | 38.10 | -0.45% |
| SSE Composite Index | 3,380.19 | 7.39 | -0.22% |